Dr. Cristofanilli continued to work on the design of the prospective clinical trial. Currently, we have a prospective Phase 2 study that will test a combination of CCR5-inhibitor combined with chemotherapy. He has worked with statistical support to better address sample size and clinical and biological endpoints. Furthermore, he continued laboratory testing of CCR5 staining/expression in circulating tumor cells (CTCs).
|Effective start/end date
|9/1/15 → 8/31/16
- Thomas Jefferson University (SUB# 080-03800-N20601 // SUB# 080-03800-N20601)
- Dr. Ralph and Marian Falk Medical Research Trust (SUB# 080-03800-N20601 // SUB# 080-03800-N20601)
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.